A First-in-Human Phase I Clinical Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-Activating Protein in Patients with Metastatic Breast Cancer

被引：0
|
作者：
Yadav, Siddhartha [1 ]
Iankov, Ianko [2 ]
Viker, Kim [2 ]
Haddad, Tufia [1 ]
Giridhar, Karthik V. [1 ]
Leon-Ferre, Roberto [1 ]
Goetz, Matthew P. [1 ]
Suman, Vera J. [3 ]
Galanis, Evanthia [1 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN USA
[2] Mayo Clin, Dept Mol Med, Rochester, MN USA
[3] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
294
引用
收藏
页码：156 / 156
页数：1
相关论文
共 39 条
  • [1] Preclinical Toxicology Assessment of Intracranial Administration of an Oncolytic Measles Virus Strain Armed with H. pylori Neutrophil-Activating Protein Prior to Phase I Trial in Glioblastoma Patients
    Viker, Kim
    Concilio, Susanna C.
    Clark, Susan M.
    Robinson, Steven
    Dyer, Roy
    Gades, Naomi
    Pattengill, Jenny
    Iankov, Ianko D.
    Galanis, Evanthia
    MOLECULAR THERAPY, 2024, 32 (04) : 825 - 825
  • [2] PHASE I TRIAL OF INTRATUMORAL AND RESECTION CAVITY ADMINISTRATION OF A MEASLES VIRUS DERIVATIVE EXPRESSING THE HUMAN CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Galanis, Evanthia
    O'Neill, Brian
    Piepgras, David
    Meyer, Fredric
    Uhm, Joon
    Marks, Randolph
    Hammack, Julie
    Lachance, Daniel
    Anderson, S. Keith
    Wu, Wenting
    Russell, Stephen
    Buckner, Jan
    NEURO-ONCOLOGY, 2008, 10 (05) : 819 - 819
  • [3] Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV)
    Liu, M. C.
    Peng, K-W
    Federspiel, M. J.
    Russell, S. J.
    Brunton, B. A.
    Zhou, Y.
    Packiriswamy, N.
    Hubbard, J. M.
    Loprinzi, C. L.
    Peethambaram, P. P.
    Ruddy, K. J.
    Allred, J. B.
    Galanis, E.
    Okuno, S. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients.
    Galanis, E.
    Hartmann, L. C.
    Cliby, W.
    Zollman, P. J.
    Peethambaram, P. P.
    Long, H. J.
    Kaur, J. S.
    Sloan, J. A.
    Peng, K. W.
    Russell, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 262S - 262S
  • [5] Phase I/II Trial Oof Intratumoral and Resection Cavity Administration of an Edmonston Oncolytic Measles Virus (MV) Derivative Expressing the Human Carcinoembryonic Antigen (CEA) in Patients with Recurrent Glioblastoma
    Galanis, Evanthia
    Anderson, Keith
    Kurokawa, Cheyne B.
    Carrero, Xiomara W.
    Uhm, Joon H.
    Federspiel, Mark J.
    Buckner, Jan C.
    Lachance, Daniel H.
    Burns, Terence C.
    Giannini, Caterina
    Iankov, Ianko D.
    Parney, Ian F.
    MOLECULAR THERAPY, 2018, 26 (05) : 160 - 161
  • [6] Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)
    Galanis, E.
    Hartmann, L. C.
    Cliby, W.
    Peethambaram, P. P.
    Long, H. J.
    Kaur, J. S.
    Haluska, P., Jr.
    Sloan, J. A.
    Peng, K.
    Russell, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.
    Somaiah, Neeta
    Block, Matthew Stephen
    Kim, Joseph W.
    Shapiro, Geoffrey
    Hwu, Patrick
    Eder, Joseph Paul
    Jones, Robin Lewis
    Gnjatic, Sacha
    Lu, Hailing
    Hsu, Frank James
    Pollack, Seth
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients
    Galanis, Evanthia
    Hartmann, Lynn C.
    Cliby, William A.
    Zollman, Paula
    Peethambaram, Prema P.
    Long, Harry J.
    Kaur, Judith S.
    Sloan, Jeff A.
    Poland, Gregory A.
    Peng, Kah-Whye
    Russell, Stephen J.
    MOLECULAR THERAPY, 2006, 13 : S281 - S281
  • [9] Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial
    Garcia-Carbonero, R.
    Gil Martin, M.
    Alvarez Gallego, R.
    Macarulla Mercade, T.
    Riesco Martinez, M. C.
    Guillen-Ponce, C.
    Vidal, N.
    Real, F. X.
    Moreno, R.
    Maliandi, V.
    Mato-Berciano, A.
    Bazan-Peregrino, M.
    Capella, G.
    Alemany, R.
    Blasi, E.
    Blasco, C.
    Cascallo, M.
    Salazar, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer.
    MacPherson, I. R.
    Bissett, D.
    Petty, R. D.
    Tait, B.
    Samuel, L. M.
    MacDonald, J.
    Smith, M.
    Birse-Archbold, J. A.
    Barnett, A. L.
    Wolf, C. R.
    Elcombe, C. R.
    Jeynes-Ellis, A.
    Evans, T. R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
1234